BCL2/Ki‑67 index predict survival in germinal center B‑cell‑like diffuse large B‑cell lymphoma

Tang,Yun‑Long; Zhou,Yan; Cheng,Ling‑Ling; Su,Yong‑Zhong; Wang,Chun‑Bin

doi:10.3892/ol.2017.6577

BCL2/Ki‑67 index predict survival in germinal center B‑cell‑like diffuse large B‑cell lymphoma

Authors:
- Yun‑Long Tang
- Yan Zhou
- Ling‑Ling Cheng
- Yong‑Zhong Su
- Chun‑Bin Wang
View Affiliations

Affiliations: Department of Hematology and Oncology, The Affiliated Hospital of Southeast University, The Third People's Hospital of Yancheng, Yancheng, Jiangsu 224000, P.R. China, Department of Oncology, Yancheng Hospital of Traditional Chinese Medicine, Yancheng, Jiangsu 224000, P.R. China, Department of Hematology, The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong 515000, P.R. China
Published online on: July 15, 2017 https://doi.org/10.3892/ol.2017.6577
Pages: 3767-3773

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diffuse large B‑cell lymphoma (DLBCL) is the most common type of non‑Hodgkin lymphoma. BCL2 apoptosis regulator (BCL2) and marker of proliferation Ki‑67 (Ki‑67) are established prognostic markers, which have traditionally been assessed separately in DLBCL. However, no studies have evaluated the prognostic value of the combination of BCL2 and Ki‑67 index. Thus, the present study aimed to analyze the prognostic value of combination of these two markers. Immunohistochemical analysis was used to assess the expression of BCL2 and Ki‑67 in 274 cases of DLBCL. The BCL2/Ki‑67 index demonstrated a significant association with decreased overall and progression free survival of patients with DLBCL, particularly for the germinal center B‑cell‑like subtype of DLBCL. Following multivariate analysis, the BCL2/Ki‑67 index retained prognostic significance. Patients with coexpression of BCL2 and Ki‑67 constituted a unique group with poor survival, thus novel therapies targeting BCL2 protein and high proliferative activity may improve the outcome of these patients.

View Figures

View References

1	Moskowitz C: Diffuse large B cell lymphoma: How can we cure more patients in 2012? Best Pract Res Clin Haematol. 25:41–47. 2012. View Article : Google Scholar : PubMed/NCBI
2	Pileri SA, Agostinelli C, Sabattini E, Bacci F, Sagramoso C, Pileri A Jr, Falini B and Piccaluga PP: Lymphoma classification: The quiet after the storm. Semin Diagn Pathol. 28:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
3	Abid MB, Nasim F, Anwar K and Pervez S: Diffuse large B cell lymphoma (DLBCL) in Pakistan: An emerging epidemic? Asian Pac J Cancer Prev. 6:531–534. 2005.PubMed/NCBI
4	Song CG, Huang JJ, Li YJ, Xia Y, Wang Y, Bi XW, Jiang WQ, Huang HQ, Lin TY and Li ZM: Epstein-barr virus-positive diffuse large B-cell lymphoma in the elderly: A matched case-control analysis. PLoS One. 10:e01339732015. View Article : Google Scholar : PubMed/NCBI
5	Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK and Vardiman J: Lymphoma classification-from controversy to consensus: The R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol. 11:(Suppl 1). S3–S10. 2000. View Article : Google Scholar
6	Coiffier B: Rituximab therapy in malignant lymphoma. Oncogene. 26:3603–3613. 2007. View Article : Google Scholar : PubMed/NCBI
7	Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 109:1857–1861. 2007. View Article : Google Scholar : PubMed/NCBI
8	He X, Chen Z, Fu T, Jin X, Yu T, Liang Y, Zhao X and Huang L: Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: Evidence from a systematic meta-analysis. BMC Cancer. 14:1532014. View Article : Google Scholar : PubMed/NCBI
9	Song MK, Chung JS, Lee JJ, Yang DH, Kim IS, Shin DH and Shin HJ: High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy. Int J Hematol. 101:140–147. 2015. View Article : Google Scholar : PubMed/NCBI
10	Li ZM, Huang JJ, Xia Y, Zhu YJ, Zhao W, Wei WX, Jiang WQ, Lin TY, Huang HQ and Guan ZZ: High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. Eur J Haematol. 88:510–517. 2012. View Article : Google Scholar : PubMed/NCBI
11	Hasselblom S, Ridell B, Sigurdardottir M, Hansson U, Nilsson-Ehle H and Andersson PO: Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma. Leuk Lymphoma. 49:1501–1509. 2008. View Article : Google Scholar : PubMed/NCBI
12	Jerkeman M, Anderson H, Dictor M, Kvaløy S, Akerman M and Cavallin-Ståhl E: Nordic Lymphoma Group study: Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma-a Nordic Lymphoma Group study. Ann Hematol. 83:414–419. 2004. View Article : Google Scholar : PubMed/NCBI
13	Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, Pharoah PD and Caldas C: A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol. 226:97–107. 2012. View Article : Google Scholar : PubMed/NCBI
14	Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, Connors JM, Staudt LM, Rimsza L, Jaffe E, et al: BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res. 17:7785–7795. 2011. View Article : Google Scholar : PubMed/NCBI
15	Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, Lynch J, Hans CP, Weisenburger DD, Greiner TC, et al: BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 24:961–968. 2006. View Article : Google Scholar : PubMed/NCBI
16	Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, et al: Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: An exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 9:435–444. 2008. View Article : Google Scholar : PubMed/NCBI
17	Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 103:275–282. 2004. View Article : Google Scholar : PubMed/NCBI
18	Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, Liu WM, Visco C, Li Y, Miranda RN, et al: MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 121:4021–4031. 2013. View Article : Google Scholar : PubMed/NCBI
19	Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, et al: Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 30:3452–3459. 2012. View Article : Google Scholar : PubMed/NCBI
20	Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, et al: Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 30:3460–3467. 2012. View Article : Google Scholar : PubMed/NCBI
21	Mationg-Kalaw E, Tan LH, Tay K, Lim ST, Tang T, Lee YY and Tan SY: Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations? Histopathology. 61:1214–1218. 2012. View Article : Google Scholar : PubMed/NCBI
22	Akyurek N, Uner A, Benekli M and Barista I: Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 118:4173–4183. 2012. View Article : Google Scholar : PubMed/NCBI
23	Wilson KS, Sehn LH, Berry B, Chhanabhai M, Fitzgerald CA, Gill KK, Klasa R, Skinnider B, Sutherland J, Connors JM and Gascoyne RD: CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma. 48:1102–1109. 2007. View Article : Google Scholar : PubMed/NCBI
24	Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, Berger F, Bosly A, Morel P, Tilly H, et al: Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 101:4279–4284. 2003. View Article : Google Scholar : PubMed/NCBI
25	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
26	Montraveta A, Xargay-Torrent S, Rosich L, López-Guerra M, Roldán J, Rodríguez V, Lee-Vergés E, de Frías M, Campàs C, Campo E, et al: Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199. Oncotarget. 6:21159–21172. 2015. View Article : Google Scholar : PubMed/NCBI
27	Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K and Gandhi V: Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic Leukemia. Clin Cancer Res. 21:3705–3715. 2015. View Article : Google Scholar : PubMed/NCBI
28	Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, Prukova D, Vejmelkova D, Jaksa R, Helman K, et al: Targeting of BCL2 family proteins with ABT-199 and homoharringtonine reveals BCL2- and MCL1-Dependent subgroups of diffuse large B-cell lymphoma. Clin Cancer Res. 22:1138–1149. 2016. View Article : Google Scholar : PubMed/NCBI
29	Shao Q, Kannan A, Lin Z, Stack BC Jr, Suen JY and Gao L: BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. Cancer Res. 74:7090–7102. 2014. View Article : Google Scholar : PubMed/NCBI